> ## Content Index
> Fetch the complete content index at: https://med-techinsights.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# VIDEO: BioInteractions Commercial Director discusses launch of AstutePlus
- URL: https://med-techinsights.com/video-biointeractions-commercial-director-discusses-launch-of-astuteplus/
- Published: 2025-02-11T15:12:05.000Z
- Updated: 2026-10-23T02:47:26.000Z
- Description: At COMPAMED 2024 in Düsseldorf, Germany, UK biomaterial company BioInteractions announced the launch of its new surface active therapeutic coating for medical devices, AstutePlus. The new development is based off of the company’s Astute technology, which it says is the strongest antithrombogenic coa
- Author: Oliver Johnson
- Tags: Insights, Medical Device Manufacturing

At [**COMPAMED**](https://med-techinsights.com/2024/12/03/medica-compamed-2024-review/?%5Fthumbnail%5Fid=10919) 2024 in Düsseldorf, Germany, UK biomaterial company [**BioInteractions**](https://biointeractions.com/?ref=med-techinsights.com) announced the launch of its new surface active therapeutic coating for medical devices, AstutePlus. The new development is based off of the company’s Astute technology, which it says is the strongest antithrombogenic coating, highest efficacy, and most effective antithrombogenic coating in the world.

The efficacy of the coating can be sustained for decades at a time, with the most recent results showing that the efficacy can be maintained for over 30 years, meaning that implants can be placed for the lifetime of a patient. 

With AstutePlus, fibrin sheath can be completely prevented from forming. With CVC catheters, there is around a 70% failure rate because of fibrin sheath alone. AstutePlus offers the ability to prevent clots, deactivate the blood, prevent a fibrin sheath from forming, ensure that nothing grows on the outside of the device, and ensure that the efficacy is maintained for as long as is needed. 

Arjun Luthra, Commercial Director of BioInteractions spoke to Med-Tech Insights: